PRMT5 and melanoma: Notably, cyclinD1/CDK4 also induces MEP50 phosphorylation which increases PRMT5 activity [67], and correspondingly, melanoma that were treated with CDK4/6 inhibitor and developed resistance also exhibited high PRMT5 activity [65].